Sugi Predict

Sugi Predict / Compounds / SCHEMBL1664773

SCHEMBL1664773

SCHEMBL1664773

CCCC(CC(=O)OCC)C[N+](=O)[O-]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MGAM O43451 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ SI P14410 1/20 0.36
▸ MGAM2 Q2M2H8 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.34
▸ TRPA1 O75762 1/20 0.34
▸ CYP3A4 P08684 3/20 0.33
▸ TSHR P16473 3/20 0.33
▸ ALOX15 P16050 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MITF O75030 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CPA1 P15085 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5105701 0.90 TSHR (0.41) MAPTKDM4ELMNAMGAMGAA
SCHEMBL17079711 0.88 TLR4 (0.41) MAPTKDM4ELMNAALDH1A1CYP3A4
SCHEMBL29632440 0.88 TLR4 (0.41) MAPTKDM4ELMNAALDH1A1CYP3A4
SCHEMBL4321183 0.85 CPA1 (0.33) MAPTLMNAALDH1A1CYP3A4TSHR
SCHEMBL1672149 0.84 KDM4E (0.35) MAPTKDM4ELMNAMGAMGAA
SCHEMBL4302076 0.83 MAPT (0.38) MAPTKDM4ELMNAMGAMGAA
SCHEMBL1228652 0.82 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA
SCHEMBL29021009 0.82 MAPT (0.37) MAPTKDM4ELMNAMGAMGAA
SCHEMBL2912395 0.82 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA
SCHEMBL1410099 0.82 CPA1 (0.45) MAPTKDM4ELMNAMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805167-B Preparation method of brivaracetam 上海新礼泰药业有限公司 2023-12-19 — — CN disclosed
EP-3302441-B1 PROCESSES TO PRODUCE BRIVARACETAM SUZHOU PENGXU PHARMATECH CO LTD (CN) 2023-12-13 — — EP disclosed
CN-111170881-B Preparation method of buvaracetam intermediate 上海医药集团股份有限公司 2023-08-01 — — CN disclosed
US-11673862-B2 Processes to produce brivaracetam SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2023-06-13 — — US disclosed
CN-116023319-A Method for preparing brivaracetam 英格尔医药科技(上海)有限公司 2023-04-28 — — CN disclosed
CN-114805167-A Preparation method of brivaracetam 上海博志研新药物技术有限公司 2022-07-29 — — CN disclosed
CN-114105852-A Refining method of brivaracetam 南京济群医药科技股份有限公司 2022-03-01 — — CN disclosed
CN-113234004-A Novel preparation process of brivaracetam 河北唯达生物医药产业技术研究有限公司 2021-08-10 — — CN disclosed
CN-112521325-A Novel preparation method of brivaracetam 北京万全德众医药生物技术有限公司 2021-03-19 — — CN disclosed
CN-111170881-A Preparation method of brivaracetam intermediate 上海医药集团股份有限公司 2020-05-19 — — CN disclosed
US-20090318708-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses UCB BIOPHARMA SPRL (BE) 2009-12-24 — — US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 — — US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 — — US disclosed
EP-1926710-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB, S.A. (BE) 2008-06-04 — — EP disclosed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 — — EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 — — EP disclosed
WO-2007031263-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB PHARMA, S.A. (BE) 2007-03-22 — — WO disclosed
WO-2007031263-A1 4-SUBSTITUTED PYRR0LIDIN-2-0NES AND THEIR USE UCB PHARMA, S.A. (BE) 2007-03-22 — — WO disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 — — WO disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673862-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR MAPT 1149/4885KDM4E 1748/4885LMNA 3886/4885
US-20090318708-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses PPOX, PYCR1, ALDH18A1 MAPT 2922/4885KDM4E 1152/4885LMNA 3646/4885
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 MAPT 2583/4885KDM4E 1184/4885LMNA 3190/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 MAPT 1512/4885KDM4E 1228/4885LMNA 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.